Helio Health and Fulgent Genetics Announce Late-Breaking Positive Performance Data of HelioLiver™ for Early Liver Cancer Detection

IRVINE, Calif. and TEMPLE CITY, Calif.: IRVINE, Calif. and TEMPLE CITY, Calif., Nov. 8, 2021 /PRNewswire/ -- Helio Health ("Helio") and its commercial partner, Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent") today announced new data at AASLD demonstrating the performance of HelioLiver in detecting early hepatocellular carcinoma (HCC). At 91% specificity,...

Click to view original post